Effect of angiolin on the functional state of the liver in experimental steatohepatitis


  • K. V. Pivtorak National Pirogov Memorial Medical University, Vinnytsya, Ukraine
Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, treatment, angiolin

Abstract

For a real impact on the functional state of the liver in steatohepatitis, the appointment of metabolic correctors is suggested. The aim of the study is to evaluate the effect of the biologically active compound angiolin on markers of cytolysis and liver function in experimental nonalcoholic steatohepatitis. Experimental studies were performed on 110 white, non-linear, mature male rats weighing 180–200 g at the start of the experiment. A model of non-alcoholic steatohepatitis was created, rats were maintained for 8 weeks on a high-calorie, high-cholesterol diet. After creating the model some of the animals were transferred to a standard semi-synthetic starch-casein diet and administered for 4 weeks the biologically active compound Angiolin. The activity of enzyme markers of cytolysis — alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (GGT) in serum was determined by standard methods. Liver biosynthetic function was assessed by the level of total protein and albumin. Statistical analysis of the obtained results was carried out with the use of the license program “STATISTICA 8” by Statsoft. After creating a model of non-alcoholic fatty liver disease in rats, an increase in body mass index occurred, high activity of ALT, AST, GGT was manifested and the concentration of total protein and albumin in the blood serum decreased compared to intact animals. An inverse correlation of mean strength was found between body mass index and total protein concentration as well as serum albumin. A strong inverse correlation between the value of ALT activity and the concentration of total protein and albumin in blood serum was established. The use of angiolin contributed to an increase in the concentration of total protein and albumin in the blood serum, an increase in the albumin / globulin coefficient, and a decrease in cytolysis. It was concluded that the biologically active compound angiolin positively affects the parameters of cytolysis and protein synthesis of the liver.

References

1. Babak, O. Ya., & Lapshina, K. A. (2016). Lechebnaya taktika u pacientov s nealkogol'noj zhirovoj bolezn'yu pecheni s uchetom urovnya citokeratina-18 v plazme krovi [Therapeutic strategy in patients with non-alcoholic fatty liver disease, considering cytokeratin-18 level determination in blood plasma]. Suchasna hastroenterolohiia - Modern Gastroenterology, 2, 15–20.

2. Barna, O. N., Syryk, V. O., & Hdyria, O. V. (2018) L-arhinin: novi mozhlyvosti zastosuvannia [L-arginine: new possibilities of application]. Liky Ukrainy - Medicine of Ukraine, 3 (219), 24–28.

3. Bilai, I. M., Mykhailiuk, Ye. O., Parchenko, V. V., Kaplaushenko, A. H., Panasenko, O. I., Knysh, Ye. H., ... Knysh, E. H. (2014). Doslidzhennia hepatoprotektornoi aktyvnosti pry eksperymentalnomu hepatyti pid vplyvom pokhidnykh 1, 2, 4-triazolu [The research of hepatoprotective activity in experimental hepatitis infl uenced by 1,2,4-triazole derivatives]. Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky – Current issues in pharmacy and medicine: science and practice, 2 (15), 57–59.

4. Makarov, V. G., & Makarova, M. N. (2013). Spravochnik. Fiziologicheskie, biohimicheskie i biometricheskie pokazateli normy eksperimental'nyh zhivotnyh. [Handbook. Physiological, biochemical and biometrics standards of experimental animals]. SPb.: OOO Izd-vo “LEMA”.

5. Pivtorak, K. V. Shevchuk, N.A., Pivtorak, N.A. (2019) Vplyv kompleksnoho zastosuvannia tiotryazolinu ta L-lizynu estsynatu na markery endotelialnoi dysfunktsii khvorykh na nealkoholnu zhyrovu khvorobu pechinky. [Effect of complex application of thiotriazoline and L-lysine escinate on markers of endothelial dysfunction in patients with non-alkogolic fatty liver disease]. Visnyk problem biolohii i medytsyny – Bulletin of problems in Biology and Medicine, 2 (150), 176–181. DOI: 10.29254/2077-4214-2019-2-1-150-176-181.

6. Pivtorak, K. V. (2015) Elektronno-mikroskopichni zminy pechinky pry eksperymentalnomu steatozi. [Submicroscopic changes in experimental hepatic steatosis]. Vіsnyk morfologіi – Reports of Morphology, 21 (1), 69–72.

7. Pivtorak, K. V. (2017). Zminy yakosti zhyttia patsiientiv na nealkoholnyi steatohepatyt pislia kompleksnoho likuvannia iz zastosuvanniam kardioprotektornykh zasobiv metabolichnoho typu [Changes in the quality of life in patients with non-alcoholic steatohepatitis using integrated cardioprotective metabolic therapy]. Biomedical and biosocial anthropology, 29, 119–123.

8. Poluhina, A. V., Vinnitskaya, E. V., Bordin, D.S., & Sandler, Yu.G. (2018). Nealkogolnaya zhirovaya bolezn pecheni u komorbidnyih patsientov: opyit terapii s ispolzovaniem Tiotriazolina [Non-Alcoholic Fatty Liver Disease in Patients with Comorbidities: the Experience of Therapy with the Use of Thiotriazolin]. Effektivnaya farmakoterapiya. Gastroenterologiya – Effective pharmacotherapy. Gastroenterology, 3 (32), 20–24.

9. Khukhlina, O. S., & Drozd, V. Iu. (2016). Optymizatsiia likuvannia nealkoholnoho steatohepatytu u khvorykh na ozhyrinnia ta ishemichnu khvorobu sertsia. [Optimization of treatment of nealkogolnogo steatogepatitu in patients with obesity and coronary heart disease]. Liky Ukrainy – Medicine of Ukraine, 9 (205), 69–75.

10. Khukhlina, O. S., Antoniv, A. A., Voievidka, O. S., & Kuzminska, O. B. (2018). Efektyvnist metabolichnoho vplyvu S-adenozylmetioninu ta meldoniiu na pokaznyky lipidnoho spektra krovi ta insulinorezystentnosti za komorbidnoho perebihu nealkoholnoho steatohepatytu, ozhyrinnia ta khronichnoi khvoroby nyrok I–II stadia [The efficiency of metabolic impact of S-adenosylmethionine and meldonium on parameters of lipid profile and insulin resistance during comorbid course of nonalcocholic steatohepatitis, obesity and chronic kidney disease stage І–ІІ]. Zaporozkyi medychnyi zhurnal – Zaporozhye Medical Journal, 20 (1), 51–57. doi:10.14739/2310-1210. 2018.1.121991.

11. Anstee, Q. M., & Day, C. P. (2012). S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. Journal of Hepatology, 57 (5), 1097–1109. doi.org/10.1016/j.jhep.2012.04.041.

12. Belenichev, I. F., Mazur, I. A., Abramov, A. V., Kucherenko, L. I., Bukhtiyarova, N. V., Egorov, A. A., ... Polyakova, E. N. (2013). The endothelium-protective effect of 3-methyl-1, 2, 4-triazolyl-5-thioacetate (S)-2, 6-diaminohexanic acid (lysinium): Effects on the expression of vascular endothelial growth factor (VEGF) and the characteristics of the endotheliocytes of the cerebral vessels of animals with cerebral ischemia. Neurochemical journal, 7 (4), 296–302.

13. Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 65 (8), 1038–1048. doi: 10,1016 / j.metabol.2015.12.012.

14. Colak, Y., Senates, E., Yesil, A., Yilmaz, Y., Ozturk, O., Doganay, L., ... Tuncer, I. (2013). Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine, 43 (1), 100–107. doi: 10.1007 / s12020-012-9712-1.

15. Kucera, O., & Cervinkova, Z. (2014). Experimental models of non-alcoholic fatty liver disease in rats. World J. Gastroenterol., 20 (26), 8364–8376. Doi: 10.3748 / wjg.v20.i26.8364.

16. Novelli, E. L. B., Diniz, Y. S., Galhardi, C. M., Ebaid, G. M. X., Rodrigues, H. G., Mani, F., ... Novelli Filho, J. L. V. B. (2007). Anthropometrical parameters and markers of obesity in rats. Laboratory animals, 41 (1), 111–119.

17. Pacifico, L., Anania, C., Martino, F., Cantisani, V., Pascone, R., Marcantonio, A., & Chiesa, C. (2010). Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology, 52 (5), 1643–1651. doi.org/10.1002/hep.23890.

18. Perazzo, H., & Dufour, J. F. (2017). The therapeutic landscape of non‐alcoholic steatohepatitis. Liver international, 37 (5), 634–647. doi.org/10.1111/liv.13270.

19. Santos, R. D., Valenti, L., & Romeo, S. (2019). Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 282, 110–120. doi.org/10.1016/j.atherosclerosis.2019.01.029.

20. Stahl, E. P., Dhindsa, D. S., Lee, S. K., Sandesara, P. B., Chalasani, N. P., & Sperling, L. S. (2019). Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. Journal of the American College of Cardiology, 73 (8), 948–963. doi.org/10.1016/j.jacc.2018.11.050.

21. Sumida, Y., & Yoneda, M. (2018). Current and future pharmacological therapies for NAFLD/NASH. Journal of gastroenterology, 53 (3), 362–376. doi.org/10.1007/s00535-017-1415-1.

22. Vinciguerra, M. (2015). Nitric oxide as a protector from nonalcoholic fatty liver disease. Hepatology, 61 (6), 2115–2116.

23. Yang, J., Fernández-Galilea, M., Martínez-Fernández, L., González-Muniesa, P., Pérez-Chávez, A., Martínez, J. A., & Moreno-Aliaga, M. J. (2019). Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. Nutrients, 11 (4), 872. doi: 10.3390/nu11040872.
Published
2019-06-27
How to Cite
Pivtorak, K. V. (2019). Effect of angiolin on the functional state of the liver in experimental steatohepatitis. Reports of Vinnytsia National Medical University, 23(2), 212-217. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2019-23(2)-05